All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
On June 4, 2020, the U.S. Food and Drug Administration (FDA) accepted a Biologics License Application (BLA) for ropeginterferon alfa-2b (P1101) for the treatment of polycythemia vera in the absence of symptomatic splenomegaly.1 The administration’s decision is expected at the beginning of next year.
Ropeginterferon alfa-2b is an investigational treatment comprising of structurally novel mono-pegylated proline interferon, designed for administration once every two weeks. The application was supported by the positive results of the phase III PROUD/CONTI-PV study, which compared the efficacy and safety of ropeginterferon alfa-2b (n = 95) with hydroxyurea/best available therapy (HU/BAT; n = 74) in patients with polycythemia vera.2 The novel agent induced higher response rates compared with HU/BAT, with rates increasing throughout 24 months of treatment. At 36 months, 66% vs 27% of patients reached a molecular response, and those responses were closely related to complete hematological response. In addition, responses were more durable with ropeginterferon alfa-2b than the comparator therapy (70.5% vs 51.4% of patients maintained a complete hematological response after 36 months). The safety profile of the investigational treatment was manageable, and similar rates of adverse events (mostly anemia, thrombocytopenia, and leukopenia) were reported in both treatment groups.
Ropeginterferon alfa-2b has previously been granted FDA’s orphan drug designation for the treatment of polycythemia vera and was approved for use in Europe in 2019.3
Polycythemia vera and essential thrombocythemia: 2021 updates
In a recent publication in the American Journal of Hematology, Tefferi and Barbui provided a review of the 2021 updates on the diagnosis, risk‐stratification, and management of...
Ropeginterferon alfa-2b is effective and safe in patients older than 60 years with PV
As discussed in our last editorial theme, the pegylated forms of interferon-alpha improve treatment compliance and lower the needed dosing. This leads to a better...
Subscribe to get the best content related to MPN delivered to your inbox